The historical rank and industry rank for Regencell Bioscience Holdings's PB Ratio or its related term are showing as below:
During the past 7 years, Regencell Bioscience Holdings's highest PB Ratio was 3060.00. The lowest was 0.00. And the median was 0.00.
RGC's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.89 * Ranked among companies with meaningful PB Ratio only.
During the past 12 months, Regencell Bioscience Holdings's average Book Value Per Share Growth Rate was -41.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -34.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Regencell Bioscience Holdings was -34.10% per year. The lowest was -34.10% per year. And the median was -34.10% per year.
Back to Basics: PB Ratio
Regencell Bioscience Holdings (NAS:RGC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Regencell Bioscience Holdings PB Ratio Related Terms
Regencell Bioscience Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's PB Ratio falls into.
Regencell Bioscience Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Regencell Bioscience Holdings (RGC) has a PB Ratio of 4,015.00 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Regencell Bioscience Holdings and its competitors. According to the industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 920 companies in the Drug Manufacturers industry.
Is Regencell Bioscience Holdings' PB Ratio too high?
Regencell Bioscience Holdings' current PB Ratio is 4,015.00. The Drug Manufacturers industry median PB Ratio is 1.89. Regencell Bioscience Holdings' value of 4,015.00 is 212333.9% above this industry median. Based on the distribution chart, Regencell Bioscience Holdings ranks #999999 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' PB Ratio compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 920 companies for PB Ratio. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median PB Ratio is 1.89. Regencell Bioscience Holdings' value of 4,015.00 is 212333.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.89, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regencell Bioscience Holdings's current PB Ratio of 4,015.00 is 212333.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current PB Ratio is 4,015.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current PB Ratio of 4,015.00. The current PB Ratio is 4,015.00 and 212333.9% above the Drug Manufacturers industry median of 1.89. Regencell Bioscience Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current PB Ratio is 4,015.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Business Description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
34GF Score
Get the complete analysis for RGC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
